vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $188.3M, roughly 1.8× BRC Group Holdings, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 13.2%, a 34.7% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -21.9%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -15.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
HAE vs RILY — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $188.3M |
| Net Profit | $44.7M | $90.3M |
| Gross Margin | 59.7% | 79.5% |
| Operating Margin | 19.9% | 32.3% |
| Net Margin | 13.2% | 47.9% |
| Revenue YoY | -2.7% | -21.9% |
| Net Profit YoY | 19.3% | 1710.8% |
| EPS (diluted) | $0.95 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $188.3M | ||
| Q3 25 | $327.3M | $215.3M | ||
| Q2 25 | $321.4M | $188.2M | ||
| Q1 25 | $330.6M | $197.2M | ||
| Q4 24 | $348.5M | $241.0M | ||
| Q3 24 | $345.5M | $225.5M | ||
| Q2 24 | $336.2M | $256.0M | ||
| Q1 24 | — | $263.4M |
| Q4 25 | $44.7M | $90.3M | ||
| Q3 25 | $38.7M | $91.1M | ||
| Q2 25 | $34.0M | $139.5M | ||
| Q1 25 | $58.0M | $-10.0M | ||
| Q4 24 | $37.5M | $-5.6M | ||
| Q3 24 | $33.8M | $-284.4M | ||
| Q2 24 | $38.4M | $-433.6M | ||
| Q1 24 | — | $-49.2M |
| Q4 25 | 59.7% | 79.5% | ||
| Q3 25 | 59.5% | 83.7% | ||
| Q2 25 | 59.8% | 81.3% | ||
| Q1 25 | 58.4% | 81.4% | ||
| Q4 24 | 55.5% | 79.8% | ||
| Q3 24 | 54.2% | 82.1% | ||
| Q2 24 | 52.0% | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | 19.9% | 32.3% | ||
| Q3 25 | 17.9% | 30.4% | ||
| Q2 25 | 16.8% | 5.7% | ||
| Q1 25 | 21.6% | -31.2% | ||
| Q4 24 | 16.9% | -69.2% | ||
| Q3 24 | 15.0% | -36.4% | ||
| Q2 24 | 11.8% | -90.8% | ||
| Q1 24 | — | -6.1% |
| Q4 25 | 13.2% | 47.9% | ||
| Q3 25 | 11.8% | 42.3% | ||
| Q2 25 | 10.6% | 74.1% | ||
| Q1 25 | 17.5% | -5.1% | ||
| Q4 24 | 10.8% | -2.3% | ||
| Q3 24 | 9.8% | -126.1% | ||
| Q2 24 | 11.4% | -169.4% | ||
| Q1 24 | — | -18.7% |
| Q4 25 | $0.95 | $2.78 | ||
| Q3 25 | $0.81 | $2.91 | ||
| Q2 25 | $0.70 | $4.50 | ||
| Q1 25 | $1.17 | $-0.39 | ||
| Q4 24 | $0.74 | $-0.01 | ||
| Q3 24 | $0.66 | $-9.39 | ||
| Q2 24 | $0.74 | $-14.35 | ||
| Q1 24 | — | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $226.6M |
| Total DebtLower is stronger | $1.2B | $1.4B |
| Stockholders' EquityBook value | $911.5M | $-171.5M |
| Total Assets | $2.5B | $1.7B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $226.6M | ||
| Q3 25 | $296.4M | $184.2M | ||
| Q2 25 | $292.9M | $267.4M | ||
| Q1 25 | $306.8M | $138.3M | ||
| Q4 24 | $320.8M | $146.9M | ||
| Q3 24 | $299.3M | $159.2M | ||
| Q2 24 | $344.4M | $236.9M | ||
| Q1 24 | — | $190.7M |
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $-171.5M | ||
| Q3 25 | $849.2M | $-260.5M | ||
| Q2 25 | $882.3M | $-351.7M | ||
| Q1 25 | $820.8M | $-496.8M | ||
| Q4 24 | $906.9M | $-488.2M | ||
| Q3 24 | $878.9M | $-497.6M | ||
| Q2 24 | $905.4M | $-218.3M | ||
| Q1 24 | — | $228.4M |
| Q4 25 | $2.5B | $1.7B | ||
| Q3 25 | $2.4B | $1.7B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.5B | $1.5B | ||
| Q4 24 | $2.5B | $1.8B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | — | $5.0B |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $26.2M |
| Free Cash FlowOCF − Capex | $87.2M | — |
| FCF MarginFCF / Revenue | 25.7% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $26.2M | ||
| Q3 25 | $111.3M | $-60.6M | ||
| Q2 25 | $17.4M | $-25.6M | ||
| Q1 25 | $116.6M | $184.0K | ||
| Q4 24 | $43.8M | $-2.7M | ||
| Q3 24 | $48.8M | $19.5M | ||
| Q2 24 | $-27.4M | $111.5M | ||
| Q1 24 | — | $135.4M |
| Q4 25 | $87.2M | — | ||
| Q3 25 | $106.3M | — | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $100.9M | — | ||
| Q4 24 | $35.2M | — | ||
| Q3 24 | $39.4M | — | ||
| Q2 24 | $-33.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | 25.7% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 30.5% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | -9.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.09× | 0.29× | ||
| Q3 25 | 2.88× | -0.66× | ||
| Q2 25 | 0.51× | -0.18× | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
